Tonpor Kasa Kazia Therapeutics ( NASDAQ: KZIA ) stock soared 142% in morning trading Wednesday after the company reported positive Phase 2/3 results for its drug paxalisib in the treatment of glioblastoma. A primary analysis of the study , called GBM-AGILE, showed a median overall survival of 14.77 months for paxalisib treated patients versus 13.
84 months for those given standard of care. A total of 313 newly diagnosed unmethylated, or NDU, patients and recurrent patients took part in the study. The company said a prespecified secondary analysis in NDU patients showed a median overall survival of 15.
54 months in the paxalisib arm, compared with 11.89 months for those undergoing concurrent standard of care. Kazia said that it intends to request a meeting with the FDA to determine if an accelerated pathway for approval is appropriate for the product.
More on Kazia Financial information for Kazia.
